Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Interferon-mediated fatigue.

U R Malik1, D F Makower, S Wadler

  • 1Department of Oncology, Montefiore Medical Center and the Albert Einstein College of Medicine, Bronx, New York 10467, USA.

Cancer
|October 13, 2001
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Prescription understanding among out-patients in government and private hospitals: A cross-sectional study in Lahore, Pakistan.

Journal of healthcare quality research·2021
Same author

Expression of retinoic acid receptor-beta 2 mRNA in normal cervical epithelium and cervical squamous cell carcinoma.

International journal of oncology·2011
Same author

Comparison of the efficacy, toxicity, and pharmacokinetics of a uracil/tegafur (UFT) plus oral leucovorin (LV) regimen between Japanese and American patients with advanced colorectal cancer: joint United States and Japan study of UFT/LV.

Journal of clinical oncology : official journal of the American Society of Clinical Oncology·2004
Same author

Phase I clinical study of infusional 5-fluorouracil with oxaliplatin and gemcitabine (FOG regimen) in patients with solid tumors.

Annals of oncology : official journal of the European Society for Medical Oncology·2003
Same author

Advances in the treatment of metastatic colorectal cancer.

Clinical colorectal cancer·2002
Same author

Perspectives for cancer therapies with cdk2 inhibitors.

Drug resistance updates : reviews and commentaries in antimicrobial and anticancer chemotherapy·2002
Same journal

Sexual orientation and gender identity based disparities in colorectal, cervical, and breast cancer screening in the United States.

Cancer·2026
Same journal

Toward exercise as standard care for older cancer survivors.

Cancer·2026
Same journal

Maintenance therapy in gynecologic malignancies: Current and future state.

Cancer·2026
Same journal

Long-term outcomes of evolving treatment regimens in Ewing sarcoma survivors diagnosed 1970-1999: A report from the Childhood Cancer Survivor Study.

Cancer·2026
Same journal

Large-scale osteosarcoma sequencing reveals age-associated genomic architectures.

Cancer·2026
Same journal

EZH2 inhibitor tazemetostat voluntarily withdrawn from market.

Cancer·2026
See all related articles

Interferon (IFN) therapy frequently causes fatigue, impacting 70-100% of patients. Managing this interferon-mediated fatigue (IMF) is complex due to its varied causes and unclear pathophysiology.

Area of Science:

  • Immunology
  • Endocrinology
  • Neuroscience

Background:

  • Fatigue affects 70-100% of patients undergoing interferon (IFN) therapy.
  • Interferon-mediated fatigue (IMF) has multifactorial origins, including endocrine, neuropsychiatric, autoimmune, and cytokine-related factors.

Purpose of the Study:

  • To explore the complex etiology of interferon-mediated fatigue (IMF).
  • To discuss the challenges in clinical management of IMF.
  • To suggest future research directions for IMF.

Main Methods:

  • Review of existing literature on interferon therapy side effects.
  • Analysis of potential contributing factors to IMF, such as thyroid dysfunction and hypothalamic-pituitary-adrenal axis suppression.
  • Examination of the link between IFN-alpha, depression, and cognitive slowing.

Related Experiment Videos

Main Results:

  • Thyroid dysfunction occurs in 8-20% of patients on IFN-alpha.
  • IFN-alpha therapy suppresses the hypothalamic-pituitary-adrenal axis.
  • IFN-alpha is associated with depression and cognitive slowing, predisposing patients to fatigue.

Conclusions:

  • Clinical management of IMF is challenging due to variable onset, severity, and poorly understood pathophysiology.
  • Current management involves dose reduction, nonpharmacologic measures, and treatment of hypothyroidism.
  • Future studies require standardized guidelines for grading and managing IMF.